Since 1874 遺伝子治療用製品の開発における 国内 …
January 6, 2012 From: the American Society of Gene & Cell Therapy and all the Society’s past Presidents To: NIH Director, Francis S Collins
Download Since 1874 遺伝子治療用製品の開発における 国内 …
Information
Domain:
Source:
Link to this page:
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-
毒物及び劇物取締法Q＆A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Risk Assessment and Management of Genotoxic ... …
www.nihs.go.jpRisk Assessment and Management of Genotoxic Impurities in Pharmaceuticals Masamitsu Honma, Ph.D. Division of Genetics and …
Related documents
Reflection paper on classification of advanced …
www.ema.europa.eu21 May 2015 . EMA/CAT/600280/2010 rev.1 . Committee for Advanced Therapies (CAT) Reflection paper on classification of advanced therapy medicinal products
Guideline on strategies to identify and mitigate …
www.ema.europa.euThe revision is intended to further assist stakeholders in the transition from non -clinical to early clinical development and in identifying factors influencing risk for new investigational medicinal products
Advanced Therapy Medicinal Products (ATMPs)
www.ich.orgAn agency of the European Union Presented by: B. Brake and A. Ganan Jimenez European Medicines Agency Advanced Therapy Medicinal Products (ATMPs)
別紙（3） PIC/S GMPガイドライン アネックス2
www.pref.kagawa.lg.jp別紙（3） pic/s gmpガイドライン アネックス2 原文 和訳 manufacture of biological medicinal substances and products for human use